Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumor activity of the combination of
experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast
cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or
MRI scans. Additional goals of this study are to look at patient safety, to determine how
long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects
the study medications may have on each other, and to find out how long patients remain cancer
free on this study treatment.